Skip to main
SEPN

Septerna Inc (SEPN) Stock Forecast & Price Target

Septerna Inc (SEPN) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Septerna Inc's current enterprise value of approximately $430 million suggests a significant potential for growth, with estimates indicating an 8-10x upside in share price if their collaboration with Novoproves proves successful. The company's management expresses confidence in executing Phase 1 trials more efficiently for their candidate SEP-786, leveraging their past experience to potentially yield better results. Moreover, if SEP-631 can match the efficacy of Xolair, a drug with nearly $3.9 billion in sales, it could reach blockbuster status, particularly due to its anticipated enhanced convenience profile.

Bears say

Septerna Inc faces several significant risks that contribute to a negative outlook for its stock, including potential delays in clinical development for its pipeline candidates such as SEP-631 and the possibility of setbacks in ongoing clinical trials. Additionally, the company's partnership with Novo Nordisk poses further uncertainties, while the risk of not securing regulatory approvals for key candidates and lower-than-expected market penetration could hinder future revenue generation. Furthermore, a recent transaction in the obesity sector highlights a potential valuation gap, which may raise concerns among investors regarding Septerna's financial prospects.

Septerna Inc (SEPN) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Septerna Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Septerna Inc (SEPN) Forecast

Analysts have given Septerna Inc (SEPN) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Septerna Inc (SEPN) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Septerna Inc (SEPN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.